Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

$CTXR
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CTXR alert in real time by email

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET

CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.

Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related bloodstream infections. A question and answer period will follow management's discussion.

Conference Call Details: 

Date:     

Monday, June 3, 2024

Time:     

8:30 a.m. Eastern Time 

1-866-777-2509 (U.S. toll free)

Dial In:   

1-412-317-5413 (international)

Webcast: 

Register for the webcast here. A replay will be available on the Citius website (www.citiuspharma.com) for 90 days following the event.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok® and LYMPHIR™. In May 2024, Citius announced positive topline results of Mino-Lok, its antibiotic lock solution to salvage catheters in patients with bloodstream infections. The Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen

ir@citiuspharma.com

908-967-6677 x113

Media Contact:

STiR-communications

Greg Salsburg

Greg@STiR-communications.com 

Citius Pharmaceuticals, a late-stage biopharmaceutical company (PRNewsfoto/Citius Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-investor-call-to-discuss-topline-results-of-phase-3-trial-of-mino-lok-antibiotic-lock-solution-302157598.html

SOURCE Citius Pharmaceuticals, Inc.

Get the next $CTXR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTXR

DatePrice TargetRatingAnalyst
12/30/2024$9.00Hold → Buy
D. Boral Capital
1/18/2022$4.00 → $6.00Buy
HC Wainwright & Co.
11/30/2021$4.00Buy
Maxim Group
More analyst ratings

$CTXR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

    CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fiscal First Quarter 2025 Business Highlights and Subsequent Developments Substantially advanced operational readiness for commercial launch of LYMPHIR in the first half of 2025;Secured a new permanent J-code, J9161, (Injection, denileukin diftitox-cxdl, for intravenous use, 1 microgram) for LYMPHIR™, assigned by the Centers for Medicare & Medicaid Serv

    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

    Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by the Centers for Medicare & Medicaid

    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.91 per share, will be exercisable immedia

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTXR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CTXR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CTXR
SEC Filings

See more

$CTXR
Leadership Updates

Live Leadership Updates

See more
  • Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

    CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. "With two late P

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

    CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financia

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTXR
Financials

Live finance-specific insights

See more
  • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

    Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

    Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related blood

    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CTXR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more